Products
Yttrium (90Y) Tacatuzumab Tetraxetan Biosimilar Radiolabelled Antibody (AFP) for Research
Pre-made Yttrium (90Y) Tacatuzumab Tetraxetan benchmark antibody (Radiolabelled antibody, anti-AFP therapeutic antibody, Anti-AFPD/FETA/HPAFP Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Yttrium (9Y) tacatuzumab tetraxetan (trade name AFP-Cide) is a humanized monoclonal antibody intended for the treatment of cancer.[1] The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-9,[2] a radioisotope which destroys the tumour cells.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1053-1mg | 1mg | 3090 |
| GMP-Bios-INN-1053-10mg | 10mg | |
| GMP-Bios-INN-1053-100mg | 100mg | |
| GMP-Bios-INN-1053-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Yttrium (90Y) Tacatuzumab Tetraxetan Biosimilar, Radiolabelled Antibody, Anti-Afp Antibody: Anti-AFPD/FETA/HPAFP therapeutic antibody |
| INN Name | Yttrium (90Y) Tacatuzumab Tetraxetan |
| Target | AFP |
| Format | Radiolabelled antibody |
| Derivation | Humanized |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Immunomedics Inc. (Morris Plains NJ USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
